Molecular Pathways: The PERKs and Pitfalls of Targeting the Unfolded Protein Response in Cancer

Nancy L. Maas and J. Alan Diehl

Abstract

The endoplasmic reticulum (ER) is a highly specialized organelle that provides an oxidizing, proteolysis environment for protein synthesis and maturation. The ER also hosts a dynamic signaling network that can sense and respond to physiologic changes that affect its environment, thereby influencing overall cell fate. Limitation of nutrients and oxygen have a direct effect on the efficiency of protein folding in the ER, and are classic inducers of the ER resident signaling pathway, the unfolded protein response (UPR). Not only does the UPR regulate ER homeostasis in normal cells experiencing such stress, but strong evidence also suggests that tumor cells can co-opt the cytoprotective aspects of this response to survive the hypoxic, nutrient-restricted conditions of the tumor microenvironment. Clin Cancer Res; 21(4): 675–9. ©2014 AACR.

Background

Signal transduction in response to ER stress

The unfolded protein response (UPR) is mediated by three primary sensors/signaling transducers: (PKR)-like ER kinase (PERK), inositol-requiring gene 1 (IRE1), and activating transcription factor 6 (ATF6), all of which span the ER membrane (Fig. 1). Under homeostatic conditions, the ER chaperone GRP78/BiP associates with the luminal domain of each of these three effectors, thereby inhibiting their activation (1, 2). ER stress can be triggered by low oxygen or restrictions in key nutrients such as glucose, which disrupts protein maturation and folding in the ER through limitations in 6 carbon sugar units or reducing equivalents, thereby increasing the need for chaperone activity and thus triggering GRP78/BiP titration. Upon GRP78/BiP titration, PERK and IRE1 are released, permitting oligomerization and trans-autophosphorylation (1). Release of GRP78/BiP from ATF6 exposes an ATF6 bZIP domain. Following proteolytic processing in the trans-Golgi, the cleaved form of ATF6 (ATF6f) is released to translocate to the nucleus, where it targets its translocation and activation by proteolytic cleavage (2).

Current evidence supports a model wherein the immediate effects of UPR activation are cytoprotective and PERK is pivotal for cell adaptation to ER stress. PERK phosphorylates the eukaryotic translation initiation factor eIF2α, which inhibits general protein synthesis and lowers the protein load (3, 4). Also important for ER stress resolution is the PERK-dependent down-regulation of cyclin D1 through eIF2α. Inhibition of cyclin D1 synthesis triggers a G1 cell-cycle arrest, thereby reducing cellular biosynthetic needs and providing a window during which to reestablish ER homeostasis (5). In addition to limiting protein influx through eIF2α, PERK directly phosphorylates the transcription factor Nrf2, which contributes to cell survival through maintaining redox homeostasis. In unstressed cells, Nrf2 is held in an inactive state through binding the cytoskeletal anchor protein Keap1. With ER stress, PERK phosphorylates Nrf2, triggering its release from Keap1. This facilitates translocation of Nrf2 to the nucleus, where it regulates the expression of detoxifying enzymes and thereby protects cells from oxidative damage (6). Through PERK, there is also a selective upregulation of certain factors, notably the bZIP transcription factor ATF4. ATF4 induces expression of prosurvival genes involved in protein folding, redox homeostasis, and amino acid metabolism (7, 8). Following prolonged or acute ER stress, ATF4 also targets the proapoptotic transcription factor GADD153/CHOP (9). CHOP expression leads to cell death, suggesting a unique role for PERK in cell fate determination.

IRE1 provides important adaptive signals through activation of the X-box protein 1 transcription factor (XBP-1). IRE1 endoribonuclease activity is responsible for processing XBP-1 via a splicing mechanism that shifts the reading frame to encode a stable, active transcription factor (XBP-1s; refs. 10–12). XBP-1 target genes include key factors involved in protein folding, ER-associated degradation (ERAD), and ER expansion under stress (13, 14). IRE1 RNase activity also contributes to ER stress resolution through regulated IRE1-dependent decay (RIDD) of mRNA (15). This pathway, in conjunction with PERK-dependent translational repression, may serve to reduce the influx of ER-bound proteins during ER stress.

Contributing to the adaptive transcriptional program, ATF6 transduces signals from the ER to the nucleus via its cytosolic bZIP domain. Following proteolytic processing in the trans-Golgi, the cleaved form of ATF6 (ATF6f) is released to translocate to the nucleus, where it targets ERAD components as well as XBP-1 itself (12, 16).
PERK in tumor cell survival and proliferation

Provided the cytoprotective effects of the UPR during stress, it is not surprising that cancer cells might co-opt the UPR for tumor perpetuation. As tumor cells begin to proliferate and expand into surrounding tissue, there is an ever-increasing demand for nutrients and oxygen. This quickly exceeds the capacity of existing tissue vasculature to support such demand, creating an environment of glucose and oxygen restriction that challenges tumor expansion. These conditions impinge on the proper folding and maturation of secreted proteins in the ER, which is immediately sensed by the three ER stress sensors. The ensuing response enables tumor cell adaptation and survival.
Consistent with the idea that UPR signaling supports tumorigenesis, major UPR mediators are often upregulated in cancer and have been implicated in critical stages of cancer progression (8, 17). The overexpression of IRE1 and ATF6, as well as of the ER chaperones GRP78/Bip, GRP94, and GRP170, in a variety of cancer types offers a case in point (18–20). These studies correlated UPR activation to a more advanced tumor grade. Functionally, UPR signaling contributes to a broad spectrum of cancer-related processes, including cell survival, migration, metastasis, autophagy, angiogenesis, and chemotherapeutic resistance. The importance of this response has been demonstrated through genetic and chemical-based manipulation of UPR components in tumor models in vivo. Recent work exploring the effect of XBP-1 and PERK deletion are prime examples of the requirement for ER stress signaling in tumor growth (21–23). Paradoxically, both PERK and IRE1 have also been suggested to contribute to tumor suppression (24–29). These observations underscore the need for more clearly defining UPR signaling branches and their underly-

As one of the master regulators of the ER stress response and a key prosurvival effector, PERK has received considerable attention in the context of tumor initiation/progression, and significant efforts have recently been focused on developing specific and potent small-molecule regulators of PERK activity. Deletion of PERK, ATF4, or Nrf2, or mutation of the PERK-mediated eIF2α phospho-site were demonstrated to have deleterious effects on cell survival following chronic ER stress in cell culture (6, 21, 30, 31). Consistent with these observations, tumor growth was significantly impaired with PERK excision in ectopic and orthotopic tumor models (21, 22). Furthermore, mammary gland–specific PERK knockout in the MMTV-Neu breast cancer model delayed tumor onset and reduced metastatic lesions. In this study, PERK knockdown triggered oxidative DNA damage and activated the DNA damage checkpoint in breast cancer cells and orthotopic tumors, suggesting a mechanism whereby tumor cell proliferation and survival are attenuated through PERK loss (22). Recent work has also demonstrated a significant prosurvival effect of PERK on ECM-detached mammary epithelial cells; PERK is activated upon cell detachment and induces autophagy via AMPK/mTORC1 regulation, thus protecting cells from anoikis (32, 33). Additional pathways through which PERK likely contributes to cell survival are the P53-Akt and NF-κB networks; however, these mechanisms have not yet been fully elucidated.

**PERK contributes to metastatic progression**

Metastasis of primary tumor cells to a distant site requires multiple steps that challenge a cell’s ability to navigate harsh conditions. Cells must detach from the primary site, migrate through surrounding tissue, enter and survive bloodstream circulation, and finally, extravasate to colonize a secondary site. Successful completion of these steps requires altered cell–cell and cell–substratum contacts and acquisition of a more migratory, invasive phenotype. Although previous work suggested a PERK-dependent effect on metastasis, it is not until very recently that the details of its prometastatic influence are beginning to become clear. These lines of investigation have centered around regulation of a previously uncharacterized metastasis-associated gene, LAMP3. LAMP3 is transcriptionally upregulated in several tumor types, as well as in response to hypoxic conditions in various cancer cell lines. This response is PERK-eIF2α–ATF4 dependent, although direct regulation by ATF4 has not yet been shown (34). Furthermore, depletion of PERK, ATF4, or LAMP3 inhibits migration in breast cancer cell lines (35), with subsequent studies demonstrating an inhibitory effect on invasion and metastasis in vivo (36).

A connection between PERK signaling and the epithelial–mesenchymal transition (EMT) has also been proposed (37). EMT is a transition from epithelial, cuboidal morphology with tight cell–cell junctions to a more motile, invasive, mesenchymal cell type. EMT contributes to normal development and to oncogenic transformation; in the latter context, it is thought to facilitate metastatic progression. Agents that induce ER stress can induce an EMT-like transition (38). Supporting these observations, recent work demonstrated specific activation of the PERK–eIF2α–ATF4 branch of the UPR in cells undergoing EMT, as well as a positive correlation between ATF4 expression and EMT genes in primary human tumors. Moreover, PERK signaling was required for the migratory and invasive properties of these cells, as well as the metastatic capability of 4T1 cells in vivo (37).

**Clinical–Translational Advances**

**Targeting PERK in cancer: small-molecule inhibitors**

The multifaceted participation of PERK in tumorigenesis makes it an attractive therapeutic target in treating cancer. This is reflected in current efforts to develop small-molecule PERK inhibitors, several of which have shown high potency and as well as selectivity in vitro and in vivo (39–41). Before crystallization of the PERK catalytic domain, initial attempts to identify ATP-competitive PERK inhibitors used homology modeling based upon the eIF2α kinase, GCN2. Docking and loop sampling studies revealed 14 compounds that inhibited PERK activity in vitro, with a maximal potency of 1 μmol/L. Selectivity of these compounds was not tested (42).

More recently, a screen of proprietary compounds for inhibitors of PERK catalytic activity toward eIF2α was performed (40). Lead optimization resulted in the identification of compounds with in vitro IC₅₀s in the nanomolar range. Each of these, eight compounds exhibited activity in cells. Importantly, these compounds displayed at least 100-fold selectivity for PERK over the closely related eIF2α kinases HRI and PKR. One of the most potent selective compounds (GSK2606414) was further assessed for its in vivo efficacy in a human tumor xenograft model. At its highest dose, GSK2606414 inhibited pancreatic tumor burden by 59%. A subsequent study of another compound identified in this screen (GSK2656157) demonstrated inhibitor-dependent restriction not only of tumor growth but also of blood vessel density and vascular perfusion (39). PERK has been shown to upregulate VEGF; therefore, the inhibitory effect of this compound on angiogenesis is not unexpected, and is further evidence of PERK inhibition. In addition, an independent high-throughput screening of approximately 80,000 compounds resulted in the identification of two lead compounds that inhibit PERK catalytic function (41). Unique to this study is the fact that both lead compounds are noncompetitive PERK inhibitors. The utility of these compounds in vivo remains to be established.

**Therapeutic considerations and alternatives**

Despite initial promising results, the small-molecule inhibitors tested in vivo have had deleterious effects on pancreatic function. The requirement for PERK in pancreatic beta cell...
fitness and survival has previously been shown through genetic mouse models in which PERK was either conventionally excised (43) or excised postnatally (44). PERK excision resulted in apoptotic loss of insulin-secreting beta cells and acinar tissue (43, 44); beta cell loss was presumably triggered by an accumulation of misfolded proinsulin and mediated through tissue (43, 44); beta cell loss was presumably triggered by an accumulation of misfolded proinsulin and mediated through tissue (43, 44). PERK-deficient mice experienced compromised glucose homeostasis that quickly led to hyperglycemia. These symptoms occurred regardless of age at PERK excision (44), suggesting that PERK function is not only required during early beta cell development but also for adult tissue homeostasis.

Consistent with these reports, PERK inhibition via small-molecule inhibitors also resulted in aberrant insulin maturation in Min6 beta cells as well as rat pancreatic islets (45), and led to degeneration of both islet and acinar cells accompanied by a 50% decrease in pancreas weight in mice (39). Although this certainly does not preclude the use of PERK inhibitors in treating neoplastic disease, it does highlight the fact that extreme caution should be used when considering treatment options. It may be possible to titrate the drug to a level of PERK inhibition that would restrict tumor burden while retaining enough activity to support pancreatic homeostasis. Transient inhibition may also lessen toxic effects on the pancreas. In addition, experimental evidence supports an approach wherein pancreatic function could be preserved through insulin supplementation (44). Administering exogenous insulin relieved the demand for insulin synthesis and secretion, which resulted in partial rescue of beta cell death. Finally, PERK inhibition may present a viable option for those with compromised pancreatic function, e.g., patients suffering from pancreatic cancer.

Although the prevailing view of PERK is as an oncogenic effector, PERK has also been proposed to play a role in tumor suppression in certain contexts. This adds an additional layer of complexity to its study not only from a purely biologic standpoint, but also from a therapeutic perspective. Early studies demonstrated oncogenic transformation of NIH-3T3 cells with inhibition of eIF2α phosphorylation (25), as well as transformation of primary human kidney cells with expression of an eIF2α phospho-mutant (26). Moreover, expression of a dominant-negative PERK mutant in mammary epithelial cells resulted in hyperproliferation, and orthotopic implantation of these cells promoted mammary tumor formation (28), whereas PERK activation inhibited tumor growth in a colon cancer model (27). Collectively, these studies suggest that a role for PERK in cancer is highly context dependent, underscoring the need for further definition of its mechanisms of action and downstream target activation under varying conditions, environments, and stages of cancer progression.

In summary, PERK is involved in multiple stages of tumor initiation, progression, and metastasis, aspects of which are just beginning to become clear. Its contribution to the oncogenic process continues to make it a viable target for therapeutic intervention; however, its essential function in pancreatic homeostasis and its potential for dual function warrant further consideration from a clinical perspective. Alternatives to PERK inhibition that are currently being explored target eIF2α (46), IRE1α (47, 48), GRP78/BiP (49–53), proteasomal degradation, and ERAD, among others (8, 54, 55). These may offer the advantage of reduced organ toxicity. The coming years will also undoubtedly see further clarification of PERK signaling mechanisms. Identification of additional interactors and downstream targets should provide the opportunity for more selectively targeting the oncogenic potential of PERK, while preserving its vital functions in cellular homeostasis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: N.L. Maas, J.A. Diehl

Writing, review, and/or revision of the manuscript: N.L. Maas, J.A. Diehl

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.A. Diehl

Study supervision: J.A. Diehl

Grant Support

This work was supported by NIH grant P01CA165997 (to J.A. Diehl).

Received June 11, 2014; revised August 1, 2014; accepted August 6, 2014; published OnlineFirst September 2, 2014.

References


Clinical Cancer Research

Molecular Pathways: The PERKs and Pitfalls of Targeting the Unfolded Protein Response in Cancer

Nancy L. Maas and J. Alan Diehl


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-3239

Cited articles
This article cites 55 articles, 24 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/4/675.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.